The company focuses on developing novel anti-infectives to address significant unmet therapeutic needs. Its lead product candidate, ibrexafungerp, is a novel oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Scynexis also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. Its team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.